Lunit has acquired Prognosia, an AI-driven breast cancer risk prediction startup founded by WashU researchers, to accelerate clinical adoption of advanced mammography analytics.
Key Details
- 1Prognosia, co-founded by WashU Medicine researchers, uses AI-driven software to analyze mammograms for five-year breast cancer risk prediction.
- 2The software, Prognosia Breast, received FDA Breakthrough Device Designation in early 2024.
- 3Past research showed Prognosia's risk model is more than twice as accurate as standard questionnaire-based approaches.
- 4The technology performs well across diverse demographic groups and is compatible with both 2D mammography and 3D tomosynthesis imaging.
- 5Lunit aims to fast-track the technology’s journey to market by integrating it with existing clinical workflows.
- 6Founders will serve in advisory roles during FDA review and further development at Lunit.
Why It Matters
This acquisition could significantly advance the integration of AI-driven, highly accurate breast cancer risk prediction into routine clinical mammography, potentially improving early detection strategies and patient outcomes. The FDA Breakthrough Designation points to the technology's promise and urgency for health systems seeking better algorithmic tools in breast imaging.
Source
EurekAlert
Related News
•EurekAlert
AI Software Matches Invasive Gold Standard in Coronary Flow Assessment
AI-based FFRangio software performs comparably to invasive pressure wire methods for evaluating coronary artery disease in a major international clinical trial.
•EurekAlert
AI Uses Routine Mammograms to Predict Women's Heart Disease Risk
AI can use mammograms to predict the risk of serious cardiovascular disease in women by quantifying breast arterial calcification.
•EurekAlert
Ultrasound AI's Delivery Date Predictor Gains FDA De Novo Clearance
Ultrasound AI's cloud-based Delivery Date AI receives FDA De Novo clearance for predicting delivery timing from standard ultrasound images.